Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - atropine sulfate monohydrate, quantity: 600 microgram/ml; sodium hydroxide - injection, solution - excipient ingredients: water for injections; sodium chloride; sulfuric acid - indications as at 30 september 2003:surgery : atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. the use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. after surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. cardiopulmonary resuscitation : atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. anticholinesterase poisoning : atropine juno is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, amanita muscaria mushrooms or other compounds with anticholinesterase activity. a cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.

Uganda - English - National Drug Authority

piramal healthcare ltd - halothane - other systemic liquid inhalations - 250ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - phenylephrine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate dihydrate; sodium metabisulfite; nitrogen; sodium chloride; citric acid - indications as at 01 jan 1991 : phenylephrine hydrochloride is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anesthesia and for the treatment of vascular failure in shock, shock-like states, and drug-induced hypotension, of hypersensitivity. it is also employed to overcome paroxysmal supraventricular tachycardia, to prolong spinal anesthesia, and as a vasoconstrictor in regional analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - oxytocin, quantity: 5 iu/ml - injection, solution - excipient ingredients: glacial acetic acid; chlorobutanol hemihydrate; water for injections; sodium acetate trihydrate; ethanol - induction of labour; inadequate uterine effort; management of third stage of labour; post-partum haemorrhage.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - oxytocin, quantity: 10 iu/ml - injection, solution - excipient ingredients: sodium acetate trihydrate; chlorobutanol hemihydrate; ethanol; glacial acetic acid; water for injections - induction of labour; inadequate uterine effort; management of third stage of labour; post-partum haemorrhage.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - terbutaline sulfate, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - indications ast at 24 june 2004: for relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm. bricanyl injection: bricanyl injection solution is recommended for acute use only.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ephedrine sulfate 30 mg/ml - solution for injection - 30 mg/ml - active: ephedrine sulfate 30 mg/ml excipient: sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - ephedrine hydrochloride 30 mg/ml - solution for injection - 30 mg/ml - active: ephedrine hydrochloride 30 mg/ml excipient: water for injection - indicated in the treatment of hypotension secondary to spinal anaesthesia in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - isoprenaline hydrochloride 0.2 mg/ml;  ; isoprenaline hydrochloride 200 µg/ml - solution for injection - 0.2 mg/ml - active: isoprenaline hydrochloride 0.2 mg/ml   excipient: lactic acid sodium chloride sodium lactate sodium metabisulfite water for injection active: isoprenaline hydrochloride 200 µg/ml excipient: citric acid disodium edetate hydrochloric acid nitrogen sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - isuprel is indicated for: 1. mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. 2. serious episodes of heart block and adams-stokes attack (except when caused by ventricular tachycardia of fibrillation). 3. use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available. 4. bronchospasm occurring during anaesthesia. 5. as an adjunct to fluid and electrolyte replacement therapy and the use of other medicines and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - midazolam 5 mg/ml;   - solution for injection - 5 mg/ml - active: midazolam 5 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - premedication before induction of anaesthesia (i.m. or especially in children, rectal, intranasal or oral administration.